Test Retest Reliability of OA and OH

NCT ID: NCT05487183

Last Updated: 2024-06-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

74 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-05

Study Completion Date

2024-04-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to measure the test retest reliability of offset analgesia (OA) and onset hyperalgesia (OH) across multiple study visits. OA and OH are quantitative sensory tests (QST) thought to measure how the brain modulates pain. This study will use a heat thermode to induce OA and OH in healthy, pain-free volunteers across 3 study visits. Additional QST measures and survey data relevant to pain modulation will be collected. This study lays the foundation required to use OA and OH as tools to measure pain modulation in clinical trials. Following their validation, we anticipate that OA and OH will serve as predictive and therapeutic biomarkers, which will aid both in the development of novel analgesics and in treatment selection leading to the personalization of pain management.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Analgesia Pain Catastrophizing Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy Volunteers

QST devices and computer tasks are used to measure OA, OH, pain intensity, and other outcomes

Group Type EXPERIMENTAL

Medoc cutaneous probe

Intervention Type BEHAVIORAL

A computer-controlled probe delivers temperatures to the skin to measure pain, OA, and OH

Quantitative sensory testing

Intervention Type BEHAVIORAL

Standard methods involving pinprick, pressure, heat, and cold applied to the skin are used to measure sensation and pain

Computer tasks

Intervention Type BEHAVIORAL

QST and computer tasks are used to measure changes in pain intensity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medoc cutaneous probe

A computer-controlled probe delivers temperatures to the skin to measure pain, OA, and OH

Intervention Type BEHAVIORAL

Quantitative sensory testing

Standard methods involving pinprick, pressure, heat, and cold applied to the skin are used to measure sensation and pain

Intervention Type BEHAVIORAL

Computer tasks

QST and computer tasks are used to measure changes in pain intensity

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy volunteers with no chronic pain issues who can understand the study procedures

Exclusion Criteria

* History of chronic pain
* Current significant pain disorder
* Active ongoing pain every day that is acute or chronic in duration
* Recent history of migraine (1 attack in last 24 months)
* Lifetime history mood disorders (anxiety, depression, bipolar) or psychotic disorders.
* Subjects taking psychotropics (e.g. benzodiazepines, antidepressants), or medications known to affect the autonomic nervous system (e.g. beta-receptor agonists or antagonists) will be excluded.
* Cognitive impairment affecting the ability to provide informed consent, understand directions, and participate in study procedures
* Uncontrolled or unstable medical disorder preventing participation in study procedures
* Pregnancy
* Tattoos on forearm
* History of brain surgery
* Nonambulatory status
* Heart problems such as an irregular heart beat or coronary artery disease
* Neurological problems such as seizure, fainting spells, recurrent severe headache, stroke, transient ischemic attack
* High blood pressure
* Severe liver disease
* Severe gastrointestinal disease
* Chronic severe infectious disease (e.g. HIV/AIDS)
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Pittsburgh

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Benedict Alter

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Benedict Alter, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UPMC Pain Medicine at Centre Commons

Pittsburgh, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STUDY22010185

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.